Merge Labs (Merge.io) -Brain-Computer Interfaces

Merge Labs (Merge.io) is a San Francisco-based research lab developing high-bandwidth, non-invasive brain-computer interfaces (BCIs) that connect with neurons using molecules rather than electrodes and transmit data via ultrasound, integrating directly with advanced AI systems without brain implants. The company emerged from stealth on January 15, 2026.

• Mission focus: Bridge biological and artificial intelligence to restore function, support brain health, and expand human agency and capability over the long term.

• Approach differentiation: Orders-of-magnitude gains in bandwidth and coverage while remaining far less invasive than electrode-based systems.

• Stage: Pre-clinical research lab; initial applications targeted at patients with injury or disease, with broader human-AI collaboration as a longer-term goal.

Core Data Grid

Merge Labs Leadership & Structural Breakdown

Key Leadership:

• Sam Altman, Co-founder: CEO of OpenAI; provides strategic AI integration and institutional backing.
• Alex Blania, Co-founder: Technology entrepreneur; CEO of Tools for Humanity.
• Sandro Herbig, Co-founder: Product and engineering leadership at Tools for Humanity.
• Tyson Aflalo, Co-founder: Former Chief Scientific Officer at Forest Neurotech; deep expertise in BCI neuroscience and neural interfaces.
• Sumner Norman, Co-founder: Neuroscience researcher; previously at Forest Neurotech.
• Mikhail Shapiro, Co-founder: Caltech researcher; pioneer in molecular engineering and ultrasound-based neuromodulation techniques.

Primary Competitors: Neuralink, Synchron, Precision Neuroscience

Core Use Cases & Market Problem:

• High-resolution neural read/write for patients with paralysis, ALS, stroke, or other neurological conditions to enable thought-to-text, prosthetic control, and communication.

• Long-term brain health monitoring and support for healthier cognitive states.

• Future seamless human-AI symbiosis for enhanced agency, creativity, and collaboration (research institutions, advanced HCI, and eventual consumer applications).

Plain English Explanation

Merge Labs is creating a non-surgical BCI system that uses engineered molecules to interface with large numbers of neurons and ultrasound to send and receive signals at high bandwidth. This allows AI to connect directly with the brain more safely and at greater scale than traditional implanted electrode systems or low-resolution surface EEG.

Target Customers & Adoption Context

Initial customers are expected to be academic medical centers, neuro-rehabilitation clinics, and device companies serving patients with severe motor or communication impairments. The core friction removed is the requirement for invasive brain surgery and its associated risks, longevity limits, and narrower accessibility—while targeting significantly higher data rates than existing non-invasive alternatives.

Capital & Traction Signals

• Record-scale $250–252 million Seed at an $850 million post-money valuation upon stealth emergence (January 2026), with OpenAI writing the largest check and committing to ongoing scientific collaboration.

• Participation from top-tier strategic and financial backers (Bain Capital, Interface Fund, Fifty Years, Gabe Newell) provides both capital and domain validation across AI, deep tech, and consumer/gaming angles.

• Rapid team expansion underway across computational neuroscience, machine learning, immunology, and hardware engineering roles—signaling focused execution on the core interdisciplinary stack.

• No public product milestones, clinical data, or revenue disclosed yet (consistent with early-stage research lab model); the primary signal is the quality and speed of capital and talent attracted to the novel non-invasive modality.

Investor Lens

In the 2026 capital cycle, neurotechnology sits at the intersection of the physical AI / embodied intelligence wave and the push for deeper human-AI infrastructure. Merge Labs differentiates through a genuinely non-invasive, high-bandwidth approach at a time when most funded peers remain anchored to electrode or endovascular platforms with existing human data. The combination of Caltech molecular/ultrasound expertise (Shapiro), prior BCI operational experience (Aflalo and Norman from Forest Neurotech), and frontier AI/consumer operators (Blania, Herbig, Altman) creates a rare interdisciplinary founding team.

OpenAI’s lead participation and collaboration commitment is the clearest near-term de-risking signal, supplying both capital and access to state-of-the-art models for neural encoding/decoding—material advantages in a field where data and algorithms are as critical as hardware. Momentum appears in the post-announcement hiring velocity and the company’s positioning ahead of further Neuralink trial readouts and sector capital concentration.

Allocator watchpoints include the pre-clinical stage (no disclosed in vivo high-bandwidth performance or safety data yet), long technical and regulatory timelines typical of novel BCI modalities, capital intensity of hardware iteration, and the distinction between therapeutic versus enhancement use cases from a policy and adoption standpoint. Public signals point to meaningful defensibility via proprietary molecular interface IP and the team’s ability to integrate biology, device physics, and AI at the frontier; asymmetric upside exists if the non-invasive path demonstrates scalable bandwidth and safety advantages over incumbent approaches.

Last Updated: June 2026

Sources:

• Merge Labs official site (https://merge.io/)
• TechCrunch coverage of the seed round and OpenAI participation (January 2026)
• Observer reporting on founding team and competitive positioning
• OpenAI statements on the investment and collaboration
• PitchBook / LinkedIn company data on team size, location, and investors
• Additional funding round confirmations from industry trackers (cross-referenced January–June 2026 reports)